← Back

Celltrion Inc

Celltrion, Inc. is a biopharmaceutical company that develops, produces, and sells medicinal products. It offers biosimilars such as Remsima, Truxima, Herzuma, Remsima SC, Yuflyma, Vegzelma, Omlyclo, Eydenzelt, Steqeyma, Stoboclo/Osenvelt, Avtozma, Zymfentra, and Regkirona, as well as CT-G07 and Donerion Patch. The company is also developing biosimilars in Phase 3 trials, including CT-P44, CT-P51, CT-P53, CT-P55, and CT-G20. Its products are distributed in approximately 100 countries, including the United States and Europe. Founded in 2002, it is headquartered in Incheon, South Korea.

Price · split & dividend adjusted
News & notes moving 068270.KO
GlobalUnited States
Biotech & Genomic Medicine▲

Autoimmune Uveitis Market to Grow at 7% CAGR Through 2036

The autoimmune uveitis market is projected to expand at a compound annual growth rate of 7% from 2026 to 2036, driven by rising diagnoses, demand for steroid-sparing therapies, and novel treatments. The market size, estimated at USD 1.2 billion in the 7MM in 2025, is forecast to grow steadily, with biologics accounting for approximately USD 800 million of that total. Nearly 673,000 diagnosed prevalent cases were reported in the 7MM in 2025, with the United States leading. Emerging therapies such as Brepocitinib (Priovant Therapeutics), TRS01 (Tarsier Pharma), and RAY121 (Chugai Pharmaceutical) are in clinical trials, aiming to address unmet needs. Recent developments include FDA IND clearance for Novaliq's NOV05, expanded pediatric approval for Celltrion's YUFLYMA, and Fast Track designation for brepocitinib.
Celltrion Inc ▲Chugai Pharmac… ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Demand
Priovant Therapeutics · Technology · Positive Brepocitinib in clinical trials and received FDA Fast Track designation for autoimmune uveitis.
068270.KO · Regulation · Positive Expanded pediatric approval for Celltrion's YUFLYMA in autoimmune uveitis.
4519.JP · Technology · Positive RAY121 in clinical trials for autoimmune uveitis, addressing unmet needs in the growing market.
Novaliq · Regulation · Positive FDA IND clearance for Novaliq's NOV05 in autoimmune uveitis.
Tarsier Pharma · Technology · Positive TRS01 in clinical trials for autoimmune uveitis, targeting unmet needs.
Read original ↗
PR Newswire·32dRead more →
South KoreaUnited States
068270.KO▼

Kospi Rises as Chip Buybacks Offset Broad Selling

South Korea's Kospi closed at 6,835.8 points on Tuesday, up 0.23%, as buyback-driven gains in Samsung Electronics and SK Hynix offset net selling from foreign, institutional, and retail investors alike. The index marked its second straight gain, having opened 0.52% lower after fresh U.S.-Iran airstrikes and a hawkish Fed speech from Chair Kevin Warsh unsettled global markets. The Kospi erased losses in the afternoon as government data showed Korea's August exports stayed solid on strong chip demand, with Samsung rising 0.38% and SK Hynix advancing 1.14%, both aided by recently announced buyback programs. Trade volume was light at 263.7 million shares worth 17.5 trillion won ($12.8 billion), with advancers narrowly beating decliners 444 to 421. Foreign investors sold a net 491.9 billion won, institutions sold 634 billion won, and retail investors sold 539.8 billion won. Oil refiners gained on rising crude prices, with SK Innovation up 7.81% and S-Oil up 1.07%, while Hanwha Aerospace fell 3.99% and Celltrion slipped 0.48%. The won weakened 1.8 won to trade at 1,370.4 per dollar as of 3:30 p.m., reflecting broader risk-off pressure from the Middle East escalation.
SK Hynix Inc ▲Samsung Electr… ▲SK Innovation ▲S-Oil Corp ▲Hanwha Aerospa… ▼Celltrion Inc ▼
000660.KO · Capital · Positive Buyback program aids shares; strong chip demand supports exports.
005930.KO · Capital · Positive Buyback program aids shares; strong chip demand supports exports.
096770.KO · Supply · Positive Rising crude prices boost oil refiners' margins and revenues.
010950.KO · Supply · Positive Rising crude prices boost oil refiners.
012450.KO · Geopolitics · Negative Middle East escalation and risk-off pressure weigh on defense stock.
068270.KO · · Negative Slipped amid broad selling, no specific driver mentioned.
Read original ↗
BeInCrypto·33dRead more →
Biotech & Genomic Medicine▲

Bevacizumab Biosimilars Market to Reach USD 5.94 Billion by 2035

The global bevacizumab biosimilars market is projected to grow from USD 2.18 billion in 2025 to USD 5.94 billion by 2035, at a compound annual growth rate of 10.54 percent, according to a new report by SNS Insider. North America held the largest share in 2025 at 41.52 percent of revenue, while Asia-Pacific is the fastest-growing region with a CAGR of around 13.28 percent. Among products, Mvasi led with a 28.46 percent revenue share in 2025, and Zirabev is expected to register the fastest CAGR through 2035. Colorectal cancer was the dominant application segment with a 37.85 percent share, and hospital pharmacies accounted for 63.74 percent of distribution. Key players include Amgen, Pfizer, Mylan, Samsung Bioepis, and Celltrion Healthcare.
AMGN ▲PFE ▲Celltrion Inc ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Biosimilars ▲Demand
AMGN · Demand · Positive Amgen's Mvasi is the leading bevacizumab biosimilar with 28.46% revenue share, and the market is projected to grow at 10.54% CAGR.
PFE · Demand · Positive Pfizer's Zirabev is expected to register the fastest CAGR through 2035 in a growing market.
068270.KO · Demand · Positive Celltrion Healthcare is a key player in the growing bevacizumab biosimilars market.
Samsung Bioepis · Demand · Positive Samsung Bioepis is a key player in the growing bevacizumab biosimilars market.
Read original ↗
GlobeNewswire·86dRead more →
Biotech & Genomic Medicine▲

Europe widens lead over US in new drug dose outsourcing

The dose outsourcing gap between European and US facilities for newly approved biosimilar and innovator drugs reached its widest point in 2025, with Europe securing 50% of contracts compared to a static 18% for the US, and the first half of 2026 is continuing that trend. Irish facilities accounted for 13% of the region's dose manufacturing contracts in 2025, up from approximately 6% in 2024, supported by an increase in its R&D Corporation tax Credit to 35% in January 2026. Germany contributed just over a fifth of European dose outsourcing for new drugs in 2025 and offers an R&D tax credit of 25–35%, while the US Alternative Simplified Credit ranges from 6% to 14%. Celltrion Inc. outsourced nine dose manufacturing contracts to European facilities in 2025, up from seven in 2024, reflecting a strategic preference for specialised European manufacturing partners.
Celltrion Inc ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › CDMO / Contract Manufacturing ▲Supply
068270.KO · Demand · Positive Celltrion increased dose manufacturing contracts outsourced to European facilities from 7 to 9 in 2025, reflecting growing demand for its products.
Read original ↗
Pharmaceutical Technology·94dRead more →
© 2026 MarketDXAsset